| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/21/24 | 8-K | Current report filing |
|
   |
3 |
| 03/20/24 | EFFECT | Notice of Effectiveness |
|
1 | |
| 03/20/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
18 | |
| 03/18/24 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 03/18/24 | UPLOAD | SEC-generated letter |
|
1 | |
| 03/15/24 | 3 | Initial statement of beneficial ownership of securities |
|
1 | |
| 03/15/24 | 8-K | Current report filing |
|
|
3 |
| 03/12/24 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
29 | |
| 03/06/24 | DEF 14A | Definitive proxy statements |
|
38 | |
| 03/01/24 | 8-K | Current report filing |
|
|
3 |
Lexaria Bioscience Corp.
Lexaria Bioscience Corp.